Immunoglobulin Market to Hit $25.15B by 2031 as Plasma Supply Surges

The global immunoglobulin market is entering a phase of robust expansion, with new projections placing its valuation at $25.15 billion by 2031. This growth is fundamentally anchored in the aggressive expansion of plasma collection capacity, the critical raw material for these life-saving therapies. Following the severe supply chain disruptions caused by the COVID-19 pandemic, major industry players have pivoted toward securing their source material through the establishment of hundreds of new collection centers globally. This infrastructure build-out is not merely a recovery effort but a strategic move to meet the escalating demand for Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) therapies.

Industry leaders such as CSL Behring, Takeda, and Grifols—often referred to as the 'Big Three' of the plasma industry—are driving this capacity surge. The market is benefiting from a dual tailwind: improved diagnostic capabilities for primary immunodeficiencies (PI) and a broadening range of clinical indications. Beyond traditional immunology, immunoglobulin is increasingly utilized in neurology for conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and in hematology for Immune Thrombocytopenia (ITP). This expansion of the therapeutic footprint ensures a steady upward trajectory for volume demand over the next decade.

“

The global immunoglobulin market is entering a phase of robust expansion, with new projections placing its valuation at $25.15 billion by 2031.

A significant technological and clinical shift is also underway as the market transitions from traditional IVIG to SCIG. Subcutaneous delivery allows for home administration, offering patients greater autonomy and reducing the burden on hospital infrastructure. For payers and healthcare systems, this shift is economically attractive as it lowers the total cost of care by eliminating infusion center fees. Manufacturers are responding by focusing their R&D pipelines on high-concentration subcutaneous formulations that require less frequent dosing, further consolidating their market positions through product differentiation.

Geographically, while North America remains the largest market due to high diagnosis rates and favorable reimbursement, the Asia-Pacific region is emerging as the fastest-growing segment. Rapidly improving healthcare infrastructure in China and India, coupled with government initiatives to increase domestic plasma self-sufficiency, is creating new frontiers for market expansion. However, the industry must navigate challenges, including the high cost of therapy and the potential long-term threat from recombinant alternatives and FcRn inhibitors, which could disrupt traditional plasma-derived markets in specific niche indications.

Looking forward, the market's success will depend on the industry's ability to maintain a delicate balance between collection costs and therapeutic pricing. As plasma collection becomes more digitized and efficient through automated donor management systems, margins are expected to stabilize. Investors and stakeholders should monitor regulatory shifts regarding donor compensation and the progress of next-generation monoclonal antibodies that may eventually compete with polyclonal immunoglobulins in certain neurological segments. For now, the essential nature of these therapies and the massive capital expenditure in collection infrastructure point toward a sustained period of bullish growth.